HC Wainwright Reaffirms “Buy” Rating for Kura Oncology (NASDAQ:KURA)

HC Wainwright reissued their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Thursday morning, Benzinga reports. The firm currently has a $32.00 price objective on the stock.

Several other research firms have also commented on KURA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Wedbush reiterated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a report on Friday, August 9th. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Finally, UBS Group began coverage on Kura Oncology in a research report on Thursday. They issued a “buy” rating and a $27.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Stock Down 1.5 %

Shares of NASDAQ KURA opened at $17.51 on Thursday. The stock has a market cap of $1.34 billion, a PE ratio of -7.85 and a beta of 0.84. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $7.52 and a 12-month high of $24.17. The company has a 50-day moving average of $19.34 and a 200 day moving average of $20.09.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same period in the previous year, the business earned ($0.53) earnings per share. The firm’s quarterly revenue was up .0% compared to the same quarter last year. As a group, sell-side analysts predict that Kura Oncology will post -2.46 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in shares of Kura Oncology during the third quarter worth $25,000. ProShare Advisors LLC lifted its stake in Kura Oncology by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after acquiring an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC boosted its holdings in Kura Oncology by 2.4% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after acquiring an additional 1,673 shares during the period. The Manufacturers Life Insurance Company grew its position in Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.